Is Liraglutide FDA approved?

Liraglutide is FDA approved (FDA status current as of 2010-01-25). This regulatory status is provided for research and educational context only.

How is 5-Amino-1MQ administered in research settings?

In research settings, 5-Amino-1MQ is typically administered via the oral route. PeptideBase does not provide dosing or administration instructions.

How is Liraglutide administered in research settings?

In research settings, Liraglutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›5-Amino-1MQ vs Liraglutide

Peptide Comparison

5-Amino-1MQ vs Liraglutide

Name: 5-Amino-1MQ vs Liraglutide — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Metabolic peptides.

5-Amino-1MQ

5-Amino-1-methylquinolinium

Fat LossResearch Only

49 providers listed

Full 5-Amino-1MQ profile →

Liraglutide

Victoza

Fat LossFDA ApprovedPrescription

Half-life: 13 hours

51 providers listed

Full Liraglutide profile →

Bottom line

Liraglutide is FDA-approved, while 5-Amino-1MQ is unknown — the clearest structural difference between them.

Quick Verdict

5-Amino-1MQ

Evidence

Preclinical

Half-life

—

Liraglutide

Evidence

Established Clinical

Half-life

13 hours

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Liraglutide
Further along in FDA review	Liraglutide
Oral administration option	5-Amino-1MQ
More provider options (49 vs 51)	Liraglutide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

5-Amino-1MQ

Liraglutide

Mechanism Family

Metabolic

Half-life

—

13 hours

FDA Status

unknown

approved

Admin Routes

oral

subcutaneous

Availability

Research Only

Prescription

Providers

49 listed

51 listed

FDA Update

—

Jan 2010

Avail. Notes

—

FDA-approved GLP-1 agonist. Victoza (NDA 022341, Jan 2010) for T2D; Saxenda (NDA 206321, Dec 2014) for weight management. Prescription only. Generic liraglutide available (generic Victoza, Dec 2024; generic Saxenda, Aug 2025).

Research Evidence

5-Amino-1MQ

PreclinicalAnimal · 1 key study · most recent 2022

Liraglutide

Established ClinicalRCT · 15 key studies · most recent 2026

Research Citations

5-Amino-1MQ

Animal2022 · Scientific Reports

NNMT inhibitor in diet-induced obese mice: effects on body weight, body fat, and energy expenditure

Liraglutide

RCT2022 · JAMA

Semaglutide vs liraglutide for weight loss in adults with overweight or obesity

RCT2015 · New England Journal of Medicine

A randomized, controlled trial of 3.0 mg of liraglutide in weight management

Cohort2026 · Diabetes Obes Metab

Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measur…

Review2026 · Diabetes Res Clin Pract

GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects…

+11 more

About 5-Amino-1MQ

Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms.

Research Areas

fat cell reductionmetabolic rateadipose tissue modulation

About Liraglutide

GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion

Research Areas

appetite suppressionweight lossblood sugar regulation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

5-Amino-1MQ

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Liraglutide

Boxed warning

Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Source: FDA label

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Price (per mg)

5-Amino-1MQ

$5.00/mg

$2.88 – $8.00 range

20 vendors

View price index →Find providers →

Liraglutide

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

5-Amino-1MQ

49 listed

Browse directory →

Providers offering

Liraglutide

51 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). 5-Amino-1MQ vs Liraglutide — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/5-amino-1mq/liraglutide

https://peptidebase.io/peptides/compare/5-amino-1mq/liraglutide Methodology License Download JSON Download CSV